Current News

Print version | PDF version | Send article | RSS-Feed

Bio*One Capital's A-Bio Pharma Secures A Second Deal With GlaxoSmithKline
$9 million Expansion of Facility Underway

18 Aug 2005 - Bio*One Capital Pte Ltd, a leading biomedical sciences investment management company, announced that its portfolio company A-Bio Pharma Pte Ltd (A-Bio), has clinched its second process development and clinical supply service agreement with GlaxoSmithKline Biologicals (GSK Bio) via the signing of an agreement with Glaxo Wellcome Manufacturing Pte Ltd. Under the contract, A-Bio will work closely with GSK Bio to develop and produce clinical lots for one of its many promising vaccine products at A-Bio's GMP biopharmaceutical facility in Singapore.
 
This deal follows the first project with GSK Bio that was announced in November 2004 as well as the master service agreement with Novo Nordisk A/S in May 2005.
 
With the securing of these agreements as well as a few more in the pipeline, there will be a further investment of S$9 million (US$5.5 million) to expand A-Bio's cell culture manufacturing capacity to meet increasing customer demand. A-Bio will add a 500L stirred tank bioreactor to its existing 200L capacity.